Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Zelek

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
La Revue Du Praticien|December 5, 2018
Cancer treatment. Surgery, radiotherapy, medical treatments (chemotherapy, targeted therapies, immunotherapy). Multidisciplinary therapeutic decision and patient informationBoris Duchemann, Laurent Zelek
La Revue Du Praticien|March 8, 2022
[Cancer treatments]Laurent Zelek, Boris Duchemann
La Revue Du Praticien|June 23, 2021
["Prescription and monitoring of the most common classes of drugs in adults and children, excluding anti-infectives (see item 177). Know the correct use of the main therapeutic classes"]Laurent Zelek, Boris Duchemann
Expert Review of Anticancer Therapy|March 22, 2003
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancerLaurent Zelek, Pascal Piedbois, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosisLaurent Zelek, Guillemette Laval, Bernard Asselain
Cancer Medicine|August 4, 2023
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapyLaurent Zelek, Rudolph Navari, Matti Aapro, et al.
EJNMMI Research|January 30, 2019
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCISTLucas Goldfarb, Boris Duchemann, Kader Chouahnia, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2022
Adoptive cell therapies in thoracic malignanciesJulie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Clinical Nutrition (Edinburgh, Scotland)|July 24, 2017
Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic reviewFrédéric Pamoukdjian, Thierry Bouillet, Vincent Lévy, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 5, 2019
Comparison of Mobility Indices for Predicting Early Death in Older Patients With Cancer: The Physical Frailty in Elderly Cancer Cohort StudyFrederic Pamoukdjian, Thomas Aparicio, Sonia Zebachi, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
La Revue Du Praticien|December 5, 2018
Cancer treatment. Surgery, radiotherapy, medical treatments (chemotherapy, targeted therapies, immunotherapy). Multidisciplinary therapeutic decision and patient informationBoris Duchemann, Laurent Zelek
La Revue Du Praticien|March 8, 2022
[Cancer treatments]Laurent Zelek, Boris Duchemann
La Revue Du Praticien|June 23, 2021
["Prescription and monitoring of the most common classes of drugs in adults and children, excluding anti-infectives (see item 177). Know the correct use of the main therapeutic classes"]Laurent Zelek, Boris Duchemann
Expert Review of Anticancer Therapy|March 22, 2003
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancerLaurent Zelek, Pascal Piedbois, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosisLaurent Zelek, Guillemette Laval, Bernard Asselain
Cancer Medicine|August 4, 2023
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapyLaurent Zelek, Rudolph Navari, Matti Aapro, et al.
EJNMMI Research|January 30, 2019
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCISTLucas Goldfarb, Boris Duchemann, Kader Chouahnia, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2022
Adoptive cell therapies in thoracic malignanciesJulie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Clinical Nutrition (Edinburgh, Scotland)|July 24, 2017
Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic reviewFrédéric Pamoukdjian, Thierry Bouillet, Vincent Lévy, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 5, 2019
Comparison of Mobility Indices for Predicting Early Death in Older Patients With Cancer: The Physical Frailty in Elderly Cancer Cohort StudyFrederic Pamoukdjian, Thomas Aparicio, Sonia Zebachi, et al.
Pageof 7